Incretin Atlas › Trials › Shining-1 (T2D)
Shining-1 (T2D)
RAY1225 · t2d
Design
- Molecule(s)
- RAY1225
- Population
- t2d
- Phase
- 2
- Participants
- 231
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAY1225 15 mg every 2 weeks | t2d china | 24 | — | — | — | −2.8 vs −0.2 | — | — | — | — | — | −7.8 vs +0.0 | verified |
| 3 mg Q2W | t2d china | 24 | 231 | — | — | −1.7 vs −0.2 | — | — | — | — | — | — | congress |
| 6 mg Q2W | t2d china | 24 | 231 | — | — | −2.0 vs −0.2 | — | — | — | — | — | — | congress |
| 9 mg Q2W | t2d china | 24 | 231 | — | — | −2.1 vs −0.2 | — | — | — | — | — | — | congress |
| 12 mg Q2W | t2d china | 24 | 231 | — | — | −2.3 vs −0.2 | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- RAY1225 15 mg every 2 weeks: Weight change not given in the abstract; SBP is placebo-adjusted
Verbatim quotes from the source (5)
- RAY1225 15 mg every 2 weeks · hba1c · Abstract, Results
-2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively
- 3 mg Q2W · hba1c · abstract
The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
- 6 mg Q2W · hba1c · abstract
The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
- 9 mg Q2W · hba1c · abstract
The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
- 12 mg Q2W · hba1c · abstract
1.92) , -2.34% (-2.56 to -2.12), -2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively, versus -0.25% (-0.43 to -0.07)
Primary sources
- Leili Gao et al. RAY1225, a bi-weekly fully biased GLP-1/GIP receptor agonist in type 2 diabetes: a phase 2 trial in Chinese adults (Shining-1). Abstract 16. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: OP 03 GLP-1 and friends: new clinical insights]
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd64086.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Shining-1 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/shining-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.